Literature DB >> 30240636

Cucurbitacin E ameliorates acute graft-versus-host disease by modulating Th17 cell subsets and inhibiting STAT3 activation.

Se-Young Kim1, Min-Jung Park1, Jeong-Eun Kwon1, Kyuong Ah Jung1, Joo-Yeon Jhun1, Seon-Yeong Lee1, Hyeon-Beom Seo1, Jae-Yoon Ryu1, Jin-Ah Beak1, Jong-Young Choi2, Mi-La Cho3.   

Abstract

Cucurbitacin E (CuE) is a biochemical compound found in plants that are members of the family CuE has been studied for its roles in anti-inflammation and the inhibition of angiogenesis as well as for its properties as an antioxidant. CuE is a new agent that was identified as a selective inhibitor of the signal transducer and activator of transcription 3 (STAT3)-related pathway. STAT3, a pivotal transcription factor for Th17 differentiation, is critical for T cell alloactivation in acute graft-versus-host disease (aGvHD). We investigated whether CuE attenuates the development of aGvHD through the suppression of Th17 cells. The alloreactive proliferation of mouse and human T cells was reduced by CuE treatment. CuE also decreased pro-inflammatory cytokines, such as IL-17 and IFN-γ, in alloreactive T cells. STAT3-responsive and IL-17A-promoter activities were also suppressed by CuE treatment, confirming that activated STAT3 was decreased by CuE treatment. To construct an aGvHD-induced mouse line, splenocytes and bone marrow cells from C57BL/6 mice were transplanted into BALB/c mice with complete mis-matched major histocompatibility complex molecules. CuE was administered to aGvHD animals 3 days per week via intraperitoneal injection. CuE attenuated the severity of aGvHD disease-related scores compared to the vehicle group. CuE inhibited skin inflammation and fibrosis, as evidenced by the expression of α-Sma and Col-I in aGvHD mice compared to the vehicle group. Additionally, aGvHD mice treated with CuE showed improved histopathological features in the small and large intestines, whereas the vehicle group showed collapsed villi in the small intestine and cryptic structures in the large intestine. We also observed a marked reduction of pro-inflammatory cytokines in the intestinal tissue. Collectively, our data suggest that CuE could serve as a therapeutic agent for patients with aGvHD.
Copyright © 2018. Published by Elsevier B.V.

Entities:  

Keywords:  Acute graft-versus-host disease; Cucurbitacin E; Fibrosis; STAT3; Th17 cells

Mesh:

Substances:

Year:  2018        PMID: 30240636     DOI: 10.1016/j.imlet.2018.09.012

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  3 in total

1.  Myeloid-derived suppressor cells therapy enhance immunoregulatory properties in acute graft versus host disease with combination of regulatory T cells.

Authors:  Min-Jung Park; Jin-Ah Baek; Se-Young Kim; Kyung-Ah Jung; Jeong Won Choi; Sung-Hwan Park; Seung-Ki Kwok; Mi-La Cho
Journal:  J Transl Med       Date:  2020-12-14       Impact factor: 5.531

2.  FK506 and Lactobacillus acidophilus ameliorate acute graft-versus-host disease by modulating the T helper 17/regulatory T-cell balance.

Authors:  Jin-Ah Beak; Min-Jung Park; Se-Young Kim; JooYeon Jhun; Jin Seok Woo; Jeong Won Choi; Hyun Sik Na; Soon Kyu Lee; Jong Young Choi; Mi-La Cho
Journal:  J Transl Med       Date:  2022-02-25       Impact factor: 5.531

3.  Ezetimibe ameliorates clinical symptoms in a mouse model of ankylosing spondylitis associated with suppression of Th17 differentiation.

Authors:  Jeonghyeon Moon; Seon-Yeong Lee; Hyun Sik Na; A Ram Lee; Keun-Hyung Cho; Jeong Won Choi; Sung-Hwan Park; Mi-La Cho
Journal:  Front Immunol       Date:  2022-08-17       Impact factor: 8.786

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.